<?xml version="1.0" encoding="UTF-8"?>
<p>Nsp3 is the largest protein encoded by CoVs (~200 kDa). In SARS-CoVs it has 16 domains which include a papain-like proteolytic enzyme from the cysteine protease class (C16 family and CA clan for SARS-CoV).
 <xref rid="B57" ref-type="bibr">
  <sup>57</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B69" ref-type="bibr">
  <sup>69</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B83" ref-type="bibr">
  <sup>83</sup>
 </xref> PL
 <sup>pro</sup> is composed of a catalytic domain, an extended right-handed thumb-palm-finger structure with a Cys-His-Asp catalytic triad, and a ubiquitin-like domain (Ubl) (
 <xref ref-type="fig" rid="f5">Fig. 5</xref>A). The catalytic Cys is located in the thumb subdomain while His and Asp in the palm subdomain (
 <xref ref-type="fig" rid="f5">Fig. 5</xref>B). PL
 <sup>pro</sup> catalyses the hydrolysis reaction of peptide bonds of pp1a/pp1ab at three sites (Nsp1/Nsp2, Nsp2/Nsp3 and Nsp3/Nsp4) that share the XLXGG* pattern (*represents the cleavage site).
 <xref rid="B57" ref-type="bibr">
  <sup>57</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B71" ref-type="bibr">
  <sup>71</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B83" ref-type="bibr">
  <sup>83</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B84" ref-type="bibr">
  <sup>84</sup>
 </xref> This activity is responsible for Nsp3 release from polyproteins. PL
 <sup>pro</sup> also recognises and hydrolyses ubiquitin and ISG15 from cellular proteins.
 <xref rid="B83" ref-type="bibr">
  <sup>83</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B84" ref-type="bibr">
  <sup>84</sup>
 </xref> The deubiquitination and deISGylation activities are proposed to modulate the post-translational modifications of signaling molecules that trigger innate immune response of the host.
 <xref rid="B85" ref-type="bibr">
  <sup>85</sup>
 </xref> These functions are pivotal for virus infection justifying the search for SARS-CoVs PL
 <sup>pro</sup> inhibitors.
 <xref rid="B84" ref-type="bibr">
  <sup>84</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B86" ref-type="bibr">
  <sup>86</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B87" ref-type="bibr">
  <sup>87</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B88" ref-type="bibr">
  <sup>88</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B89" ref-type="bibr">
  <sup>89</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B90" ref-type="bibr">
  <sup>90</sup>
 </xref> Putative inhibitors of SARS-CoV-2 PL
 <sup>pro</sup> include FDA-approved drugs such as fostamatinib disodium (6) (a tyrosine kinase inhibitor used in the treatment of chronic immune thrombocytopenia) and natural products [e.g., platycodin D (7)].
 <xref rid="B89" ref-type="bibr">
  <sup>89</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B91" ref-type="bibr">
  <sup>91</sup>
 </xref>
</p>
